Zortress (Novartis Pharmaceuticals Corporation)
Welcome to the PulseAid listing for the Zortress drug offered from Novartis Pharmaceuticals Corporation. This Kinase Inhibitor [EPC],Protein Kinase Inhibitors [MoA],Cytochrome P450 3A4 Inhibitors [MoA],P-Glycoprotein Inhibitors [MoA],Cytochrome P450 2D6 Inhibitors [MoA],mTOR Inhibitor Immunosuppressant [EPC],mTOR Inhibitors [MoA],Decreased Immunologic Activity [PE] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: | Novartis Pharmaceuticals Corporation |
NON-PROPRIETARY NAME: | everolimus |
SUBSTANCE NAME: | EVEROLIMUS |
TYPE: | HUMAN PRESCRIPTION DRUG |
PHARMA CLASS: | Kinase Inhibitor [EPC],Protein Kinase Inhibitors [MoA],Cytochrome P450 3A4 Inhibitors [MoA],P-Glycoprotein Inhibitors [MoA],Cytochrome P450 2D6 Inhibitors [MoA],mTOR Inhibitor Immunosuppressant [EPC],mTOR Inhibitors [MoA],Decreased Immunologic Activity [PE] |
ROUTE: | ORAL |
DOSAGE FORM: | TABLET |
MARKETING CATEGORY NAME: | NDA |
START MARKETING DATE: | 2010-04-22 |
END MARKETING DATE: | 0000-00-00 |
Zortress HUMAN PRESCRIPTION DRUG Details:
Item Description | Zortress from Novartis Pharmaceuticals Corporation |
LABELER NAME: | Novartis Pharmaceuticals Corporation |
DEA SCHEDULE: |
|
ACTIVE STRENGTH: | 0.5(mg/1) |
START MARKETING DATE: | 2010-04-22 |
END MARKETING DATE: | 0000-00-00 |
PRODUCT ID: | 0078-0414_11176f89-ad23-4d84-a0b0-47885abfc983 |
PRODUCT NDC: | 0078-0414 |
APPLICATION NUMBER: | NDA021560 |
Other EVEROLIMUS Pharmaceutical Manufacturers / Labelers: